BioViva would like to thank Dr Michael Fossel for this blog spot and in recognizing the importance of our work. BioViva will be using FDA standards and an IRB in all of our clinical trials. Bioviva is choosing to do them offshore so that we can spend less money and create treatments that people can afford. This offshore method is used by many of the biggest pharmaceutical companies as well.

Michael explains why there is a difference in the approach of the two companies but importantly why there is room for both methods. It is not about being first, being first is irrelevant, it’s about developing therapies that could ultimately save lives!

- PhD student researching Aging, Mitochondria, and Regenerative Medicine -
I currently write for The Conversation (http://bit.ly/13WVyUW) and I have
written for The Guardian (http://bit.ly/13WVtRh) - Ringleader of the Oxford
University Scientific Society - Co-conspirator at the Oxford Transhumanism
and Emerging Technologies - Designing exciting events with the British
Science Association Oxford - Advisory Board member at Lifeboat Foundation's
Life Extension Board, and the Sustainability Board - Also, I am an Ultimate
(frisbee) enthusiast - Yes, unfortunately that's me trying to catch the
frisbee